Investor & News Press Releases Elizabeth Campbell 10/5/22 Elizabeth Campbell 10/5/22 NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients Read More Elizabeth Campbell 8/29/22 Elizabeth Campbell 8/29/22 NewAmsterdam Pharma Showcases Leadership in Cardiometabolic Disease Treatment in Multiple Presentations at ESC Congress 2022 Read More Elizabeth Campbell 8/11/22 Elizabeth Campbell 8/11/22 NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib Read More Elizabeth Campbell 7/28/22 Elizabeth Campbell 7/28/22 NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia Read More Elizabeth Campbell 7/25/22 Elizabeth Campbell 7/25/22 NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Oral Therapies for Cardiometabolic Diseases Read More Elizabeth Campbell 6/28/22 Elizabeth Campbell 6/28/22 NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe Read More Older Posts
Elizabeth Campbell 10/5/22 Elizabeth Campbell 10/5/22 NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients Read More
Elizabeth Campbell 8/29/22 Elizabeth Campbell 8/29/22 NewAmsterdam Pharma Showcases Leadership in Cardiometabolic Disease Treatment in Multiple Presentations at ESC Congress 2022 Read More
Elizabeth Campbell 8/11/22 Elizabeth Campbell 8/11/22 NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib Read More
Elizabeth Campbell 7/28/22 Elizabeth Campbell 7/28/22 NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia Read More
Elizabeth Campbell 7/25/22 Elizabeth Campbell 7/25/22 NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Oral Therapies for Cardiometabolic Diseases Read More
Elizabeth Campbell 6/28/22 Elizabeth Campbell 6/28/22 NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe Read More
